Drugs / Daratumumab/rHuPH20
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06107738 | Dec 2023 → Dec 2027 expected | plasma cell myeloma | Barbara Ann Karmanos Cancer Institute | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Daratumumab/rHuPH20 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06107738 ↗ |
| Route | Subcutaneous | “Daratumumab/rHuPH20 1800 mg SC days 1, 8, 15, 22” NCT06107738 ↗ |